Investors & Media

Investors & Media

Welcome to our investor page

Harnessing the immune system’s full potential to fight human disease.

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.


Press Releases

30 November 2022

BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and C..

18 November 2022

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Boost..

16 November 2022

Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Stud..

Press releases (more)

Upcoming Events

January 9 - January 12, 2023

JP Morgan Annual Healthcare Conference

San Francisco, CA

Upcoming events (more)

Stock Quote

Nov 30, 2022 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.